Effects of paliperidone palmitate on coagulation: an experimental study. 2014

Enver Demirel Yılmaz, and Sedat Motor, and Fatih Sefil, and Neslihan Pınar, and Hanifi Kokacya, and Mustafa Kisa, and Suleyman Oktar
Department of Psychiatry, Faculty of Medicine, Bezmialem University, Istanbul, Turkey.

OBJECTIVE The aim of the present study was to examine the effects of a new antipsychotic drug paliperidone palmitate on hemogram and coagulation parameters in rats. METHODS Experiments were performed on 22 female albino Wistar rats (8-12 weeks old). Control group was given drinking water as vehicle (0.3 mL). PAL-1 rats were given 1 mg/kg paliperidone palmitate (in 0.3 mL drinking water) by oral gavage once a day for ten days and PAL-3 rats received 3 mg/kg paliperidone palmitate (in 0.3 mL drinking water) by oral gavage for ten days. Blood samples were drawn from the heart 24 hours after the last drug dose, and hemogram and coagulation parameters were measured with automated analyzers. RESULTS Hemogram did not change in the paliperidone treated groups compared to the controls. Factor VIII levels decreased in the PAL-1 and PAL-3 groups; and this decrease was significantly greater in the PAL-3. Factor IX levels decreased in PAL-3 rats, but its levels also increased in PAL-1 rats compared to the control. CONCLUSIONS Paliperidone has led to changes in the serum levels of coagulation factors VIII and IX in rats. As a result, paliperidone may be causing thromboembolism or bleeding in a dose-independent manner.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D010168 Palmitates Salts and esters of the 16-carbon saturated monocarboxylic acid--palmitic acid. Hexadecanoates,Palmitate
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D004909 Erythrocyte Indices ERYTHROCYTE size and HEMOGLOBIN content or concentration, usually derived from ERYTHROCYTE COUNT; BLOOD hemoglobin concentration; and HEMATOCRIT. The indices include the mean corpuscular volume (MCV), the mean corpuscular hemoglobin (MCH), and the mean corpuscular hemoglobin concentration (MCHC). Erythrocyte Hemoglobin, Mean Cell,Erythrocyte Size Determination,Erythrocyte Volume, Mean Cell,Hemoglobin, Erythrocyte, Mean Cell,Mean Corpuscular Volume,Red Cell Indices,Erythrocyte Diameter,Erythrocyte Index,Erythrocyte Indexes,Erythrocyte Thickness,Mean Cell Hemoglobin Concentration,Mean Cell Volume,Mean Corpuscular Hemoglobin,Mean Corpuscular Hemoglobulin Concentration,Red Cell Distribution Width,Red Cell Index,Red Cell Indexes,Cell Volumes, Mean,Corpuscular Volumes, Mean,Determination, Erythrocyte Size,Determinations, Erythrocyte Size,Diameter, Erythrocyte,Diameters, Erythrocyte,Erythrocyte Diameters,Erythrocyte Size Determinations,Hemoglobin, Mean Corpuscular,Hemoglobins, Mean Corpuscular,Index, Erythrocyte,Index, Red Cell,Indexes, Erythrocyte,Indexes, Red Cell,Indices, Erythrocyte,Indices, Red Cell,Mean Cell Volumes,Mean Corpuscular Hemoglobins,Mean Corpuscular Volumes,Size Determination, Erythrocyte,Size Determinations, Erythrocyte,Thickness, Erythrocyte,Volume, Mean Cell,Volume, Mean Corpuscular,Volumes, Mean Cell,Volumes, Mean Corpuscular
D005260 Female Females
D000068882 Paliperidone Palmitate A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA. 3-(2-(4-(6-fluoro-3-(1,2-benzisoxazolyl))-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one,9-Hydroxy-risperidone,9-Hydroxyrisperidone,9-OH-risperidone,Invega,Invega Sustenna,Paliperidone,R 76477,R-76477,9 Hydroxy risperidone,9 Hydroxyrisperidone,9 OH risperidone,Palmitate, Paliperidone,R76477,Sustenna, Invega
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Enver Demirel Yılmaz, and Sedat Motor, and Fatih Sefil, and Neslihan Pınar, and Hanifi Kokacya, and Mustafa Kisa, and Suleyman Oktar
March 2010, CNS drugs,
Enver Demirel Yılmaz, and Sedat Motor, and Fatih Sefil, and Neslihan Pınar, and Hanifi Kokacya, and Mustafa Kisa, and Suleyman Oktar
November 2012, Schizophrenia bulletin,
Enver Demirel Yılmaz, and Sedat Motor, and Fatih Sefil, and Neslihan Pınar, and Hanifi Kokacya, and Mustafa Kisa, and Suleyman Oktar
October 2013, Issues in mental health nursing,
Enver Demirel Yılmaz, and Sedat Motor, and Fatih Sefil, and Neslihan Pınar, and Hanifi Kokacya, and Mustafa Kisa, and Suleyman Oktar
June 2012, The Cochrane database of systematic reviews,
Enver Demirel Yılmaz, and Sedat Motor, and Fatih Sefil, and Neslihan Pınar, and Hanifi Kokacya, and Mustafa Kisa, and Suleyman Oktar
December 2012, Expert review of neurotherapeutics,
Enver Demirel Yılmaz, and Sedat Motor, and Fatih Sefil, and Neslihan Pınar, and Hanifi Kokacya, and Mustafa Kisa, and Suleyman Oktar
January 2019, Case reports in psychiatry,
Enver Demirel Yılmaz, and Sedat Motor, and Fatih Sefil, and Neslihan Pınar, and Hanifi Kokacya, and Mustafa Kisa, and Suleyman Oktar
July 2014, International clinical psychopharmacology,
Enver Demirel Yılmaz, and Sedat Motor, and Fatih Sefil, and Neslihan Pınar, and Hanifi Kokacya, and Mustafa Kisa, and Suleyman Oktar
November 2019, International clinical psychopharmacology,
Enver Demirel Yılmaz, and Sedat Motor, and Fatih Sefil, and Neslihan Pınar, and Hanifi Kokacya, and Mustafa Kisa, and Suleyman Oktar
June 2021, Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater,
Enver Demirel Yılmaz, and Sedat Motor, and Fatih Sefil, and Neslihan Pınar, and Hanifi Kokacya, and Mustafa Kisa, and Suleyman Oktar
January 2018, Clinical schizophrenia & related psychoses,
Copied contents to your clipboard!